Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2000 1
2002 14
2003 10
2004 23
2005 38
2006 51
2007 47
2008 80
2009 74
2010 107
2011 123
2012 132
2013 154
2014 191
2015 211
2016 196
2017 232
2018 287
2019 313
2020 354
2021 417
2022 350
2023 2
Text availability
Article attribute
Article type
Publication date

Search Results

3,055 results
Results by year
Filters applied: . Clear all
Page 1
Mesenchymal stem cell therapy for severe COVID-19.
Shi L, Wang L, Xu R, Zhang C, Xie Y, Liu K, Li T, Hu W, Zhen C, Wang FS. Shi L, et al. Signal Transduct Target Ther. 2021 Sep 8;6(1):339. doi: 10.1038/s41392-021-00754-6. Signal Transduct Target Ther. 2021. PMID: 34497264 Free PMC article. Review.
Macrophage MST1/2 Disruption Impairs Post-Infarction Cardiac Repair via LTB4.
Liu M, Yan M, He J, Lv H, Chen Z, Peng L, Cai W, Yao F, Chen C, Shi L, Zhang K, Zhang X, Wang DW, Wang L, Zhu Y, Ai D. Liu M, et al. Among authors: shi l. Circ Res. 2021 Oct 29;129(10):909-926. doi: 10.1161/CIRCRESAHA.121.319687. Epub 2021 Sep 13. Circ Res. 2021. PMID: 34515499 Free article.
KIR3DL3-HHLA2 is a human immunosuppressive pathway and a therapeutic target.
Wei Y, Ren X, Galbo PM Jr, Moerdler S, Wang H, Sica RA, Etemad-Gilbertson B, Shi L, Zhu L, Tang X, Lin Q, Peng M, Guan F, Zheng D, Chinai JM, Zang X. Wei Y, et al. Among authors: shi l. Sci Immunol. 2021 Jul 9;6(61):eabf9792. doi: 10.1126/sciimmunol.abf9792. Sci Immunol. 2021. PMID: 34244312
A minimal common outcome measure set for COVID-19 clinical research.
WHO Working Group on the Clinical Characterisation and Management of COVID-19 infection. WHO Working Group on the Clinical Characterisation and Management of COVID-19 infection. Lancet Infect Dis. 2020 Aug;20(8):e192-e197. doi: 10.1016/S1473-3099(20)30483-7. Epub 2020 Jun 12. Lancet Infect Dis. 2020. PMID: 32539990 Free PMC article. Review.
Efficacy of Concurrent Chemoradiotherapy With S-1 vs Radiotherapy Alone for Older Patients With Esophageal Cancer: A Multicenter Randomized Phase 3 Clinical Trial.
Ji Y, Du X, Zhu W, Yang Y, Ma J, Zhang L, Li J, Tao H, Xia J, Yang H, Huang J, Bao Y, Du D, Liu D, Wang X, Li C, Yang X, Zeng M, Liu Z, Zheng W, Pu J, Chen J, Hu W, Li P, Wang J, Xu Y, Zheng X, Chen J, Wang W, Tao G, Cai J, Zhao J, Zhu J, Jiang M, Yan Y, Xu G, Bu S, Song B, Xie K, Huang S, Zheng Y, Sheng L, Lai X, Chen Y, Cheng L, Hu X, Ji W, Fang M, Kong Y, Yu X, Li H, Li R, Shi L, Shen W, Zhu C, Lv J, Huang R, He H, Chen M. Ji Y, et al. Among authors: shi l. JAMA Oncol. 2021 Oct 1;7(10):1459-1466. doi: 10.1001/jamaoncol.2021.2705. JAMA Oncol. 2021. PMID: 34351356 Free PMC article. Clinical Trial.
GPCR-mediated β-arrestin activation deconvoluted with single-molecule precision.
Asher WB, Terry DS, Gregorio GGA, Kahsai AW, Borgia A, Xie B, Modak A, Zhu Y, Jang W, Govindaraju A, Huang LY, Inoue A, Lambert NA, Gurevich VV, Shi L, Lefkowitz RJ, Blanchard SC, Javitch JA. Asher WB, et al. Among authors: shi l. Cell. 2022 May 12;185(10):1661-1675.e16. doi: 10.1016/j.cell.2022.03.042. Epub 2022 Apr 27. Cell. 2022. PMID: 35483373 Free article.
Mutant IDH Inhibits IFNγ-TET2 Signaling to Promote Immunoevasion and Tumor Maintenance in Cholangiocarcinoma.
Wu MJ, Shi L, Dubrot J, Merritt J, Vijay V, Wei TY, Kessler E, Olander KE, Adil R, Pankaj A, Tummala KS, Weeresekara V, Zhen Y, Wu Q, Luo M, Shen W, García-Beccaria M, Fernández-Vaquero M, Hudson C, Ronseaux S, Sun Y, Saad-Berreta R, Jenkins RW, Wang T, Heikenwälder M, Ferrone CR, Goyal L, Nicolay B, Deshpande V, Kohli RM, Zheng H, Manguso RT, Bardeesy N. Wu MJ, et al. Among authors: shi l. Cancer Discov. 2022 Mar 1;12(3):812-835. doi: 10.1158/2159-8290.CD-21-1077. Cancer Discov. 2022. PMID: 34848557 Free PMC article.
3,055 results